Ocugen Signs $20 Million Securities Purchase Deal with Janus Henderson Investors

Ocugen’s and Janus Securities' Purchase Agreement

Announcement

Ocugen Inc., a global biotechnology company in gene therapies for blindness diseases, signed a securities purchase agreement with Janus Henderson Investors, a leading asset management firm. Janus will purchase 20,000,000 shares of common stock and warrants from Ocugen to purchase up to an estimated 20,000,000 shares of common stock at a purchase price of $1.00 per share. The assisted closing price will be on 7th August 2025, and the warrant is under a registered direct offering. The warrants consist of an exercise price of $1.50 per share, which is immediate on issuance, with an expiry duration of two years following the date of issuance. The warrant is responsive by the company on VWAP company’s common stock increase by $2.50 per share over five of the ongoing 30 trading day period.

Ocugen’s offering to the Janus Henderson investors will balance a valuable healthcare trading ecosystem. The utilization of this offering by Janus might strengthen its investment platform in further drug development initiatives and will turn into new transformational therapy or findings to take place in the huge healthcare market journey. The offerings detailed registration, effective dates, and access to the details are specified below.

Offering

The Nobel Capital Markets Inc. will act as the sole placement agent regarding the offering. The gross proceeds to the company are predicted to reach an estimated value of $20 million prior to the deduction of the placement agent fees and other listed offering expenses. The company might receive around $30 million of its added gross proceeds on the fully exercised warrant. The offering is expected to close on or about 11th August 2025, on satisfactory customer closing conditions. The offering is pursued on an effective shelf registration statement on Form S-3 (File no. 333-278774), early filed with the US Securities and Exchange Commission (SEC), which was announced effective on 1st May 2024.

The offering is documented in the form of a prospectus forming as a part of the official registration statement regarding the offering. A prospectus supplement following the shares of common stock and warrants will be filed by the company with the SEC. Once available, copies of the prospectus supplement on the registered direct offering, along with the prospectus, can be accessed from the SEC’s website at www.sec.gov Or else at Noble Capital Markets Inc., 150 East Palmetto Park Rd, Suite 110, Boca Raton, FL 33432.